Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nVNS, Cannabidiol, and Standard of Care for Persistent Post-Traumatic Headache in Elite Athletes
NCT07624279Phase 2Not yet recruiting
- Sponsor
- American Society of Pain and Neuroscience
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cannabidiol in Persistent Post-Traumatic Headache (3 arms), sponsored by American Society of Pain and Neuroscience. Primary endpoint: Moderate-severe headache days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Persistent Post-Traumatic Headache
Beyond the preview
Go deeper on NCT07624279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624279.